US push to cut drug prices could mean longer waits for European patients

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-14T05:16:53.527Z • Permanent link

US President Joe Biden's administration has taken a significant step towards tackling rising healthcare costs by launching a push to cut drug prices. The move, which has been in the works for months, aims to give the FDA more authority to negotiate prices with pharmaceutical companies. The new policy, which was announced in February, has been met with enthusiasm from patient advocacy groups and lawmakers, but it's unclear how it will affect patients in Europe. According to a new study published in the Journal of the American Medical Association, US efforts to drive down drug prices could lead to longer waits for new medicines in Europe.

The study, which used data from the US FDA and European Medicines Agency, found that pharmaceutical companies may delay launches of new medicines in the US in order to wait for price regulation in the US. This could lead to a delay in the availability of new treatments for patients in Europe, who may have to wait longer for access to the same medicines. The study's authors suggest that this could be a significant concern, particularly for patients with life-threatening diseases.

Pharmaceutical companies have already expressed concerns about the potential impact of the new policy on their business. Eli Lilly, a major pharmaceutical company, has warned that the policy could lead to a decrease in the number of new medicines being developed. The company's CEO, David Ricks, has stated that the policy could make it more difficult for companies to recoup their investment in research and development. The FDA has responded to these concerns by stating that the policy is designed to ensure that patients have access to affordable medicines, while also allowing companies to recoup their investment.

The potential impact of the new policy on the availability of new medicines in Europe could have significant real-world consequences. Patients in Europe may face longer waits for access to new treatments, which could lead to poorer health outcomes and increased mortality rates. This could be particularly concerning for patients with rare diseases, who may have limited access to treatments and may be forced to rely on unproven or experimental therapies.

The study's findings also have implications for the pharmaceutical industry as a whole. If pharmaceutical companies are forced to delay launches of new medicines in the US, it could lead to a decrease in the number of new treatments being developed. This could have long-term consequences for the industry, which relies on the development of new medicines to drive growth and innovation. The study's authors suggest that the policy could also lead to increased competition among pharmaceutical companies, as they seek to develop new medicines and gain a competitive advantage.

The push to cut drug prices is part of a larger trend towards increased regulation of the pharmaceutical industry. In recent years, there have been numerous efforts to increase transparency and accountability in the industry, including the passage of the 21st Century Cures Act in the US. This law, which was signed into effect in 2016, requires pharmaceutical companies to disclose more information about their research and development processes, including the costs of developing new medicines.